Skip to main content

Table 1 Baseline clinical characteristics

From: The effect of dapagliflozin treatment on epicardial adipose tissue volume

 

Dapagliflozin (N = 20)

Conventional therapy (N = 20)

p value

Age (years)

68 ± 4

66 ± 6

0.30

Male/female (n)

16/4

14/6

0.48

Body weight (kg)

71.4 ± 14.4

69.5 ± 12.2

0.37

BMI

26.6 ± 4.6

25.0 ± 3.1

0.25

Hypertension

14 (70)

12 (60)

0.52

Smoking, ever

6 (30)

5 (25)

0.73

Lipid profile

 LDL (mg/dl)

91 ± 26

84 ± 20

0.44

 TG (mg/dl)

152 ± 92

151 ± 81

0.83

 HDL (mg/dl)

46 ± 14

40 ± 10

0.17

 TG/HDL

3.6 ± 2.1

3.7 ± 2.1

0.73

Glycemic marker

 HbA1c (%)

7.2 ± 0.6

7.4 ± 1.1

0.51

 FBS (mg/dl)

144 ± 41

136 ± 24

0.48

 HOMA-IR

2.6 ± 1.9

2.5 ± 1.8

0.79

 iHOMA 2%S

113 ± 94

134 ± 75

0.52

 Keton body (μmol/l)

126 ± 116

120 ± 105

 

Adipose-associated marker

 EAT volume (cm3)

115 ± 22

108 ± 25

0.38

 TNF-α (pg/ml)

2.4 ± 0.7

2.2 ± 0.7

0.78

 PAI-1 (ng/ml)

42.2 ± 16.1

45.7 ± 14.6

0.41

 BNP (pg/ml)

82 ± 88

102 ± 129

0.62

 Alb/Cre ratio (mg/g CRE)

21 ± 39

38 ± 68

0.50

  1. Data are presented as mean ± SD or the number (percentage)
  2. LDL low density lipoprotein cholesterol, HDL high density lipoprotein cholesterol, HOMA-IR homeostatic model assessment insulin resistance, iHOMA-2 interactive 24-variable model homeostatic model assessment insulin resistance-2, EAT epicardial adipose tissue, TNF-α tumor necrotic factor-α, PAI-1 plasminogen activator inhibitor-1, BNP brain natriuretic peptide, Alb/Cre ratio albumin/creatinine ratio